Ad hoc announcement pursuant to Art. 53 LR February 16, 2024 Annual report of BB Biotech AG as at December 31, 2023  BB Biotech AG publishes its 2023 annual report BB Biotech AG published its annual report for fiscal year 2023 today. Besides the audited consolidated financial statements, the annual report contains detailed information on the bi [ … ]

Release as at February 14, 2024Investor interest returns – dividend yield remains high for 2024 After a difficult 2023 stock market year, above all due to higher interest rates, the capital markets are now once again looking at biotech companies with interest. The prospect of falling interest rates has led to a rethink. While the majority of inves [ … ]

Ad hoc announcement pursuant to Art. 53 LR January 19, 2024 BB Biotech AG publishes financial results for 2023 and changes to the Board of Directors In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information: Results for the financial year 2023 Based on its preliminary unaudited  [ … ]

Media release as at January 19, 2024 Portfolio of BB Biotech AG as at December 31, 2023 End of year biotech equity market rally – M&A and end of rate hike cycle In 2023, global equity performed better than anticipated by many. The US central bank moderated and then paused interest rate hikes. These developments resulted in a year-end bond ma [ … ]